Brain Tumor Surgery
Complete guide to brain tumor surgery — who needs it, craniotomy approaches, awake surgery, 5-ALA fluorescence, cost comparison, and recovery. Plan with Gaf Healthcare.
Estimated cost: $6,000 – $10,000 · Average stay: 8–12 days
Brain tumour surgery — neurosurgical resection of an intracranial neoplasm — requires integration of advanced neuroimaging, electrophysiological monitoring, real-time surgical navigation, and meticulous microsurgical technique. It is performed for both primary brain tumours (gliomas, meningiomas, schwannomas, pituitary adenomas) and brain metastases — cancer deposits that have spread from tumours elsewhere.
The goal of surgery varies with tumour biology: for benign tumours (meningiomas, acoustic neuromas, pituitary adenomas), complete resection is curative. For malignant primary brain tumours (glioblastoma, high-grade gliomas), complete surgical resection is rarely possible due to infiltrative growth, but maximal safe resection — removing as much tumour as safely possible while preserving neurological function — extends survival and quality of life. For brain metastases, surgical resection or stereotactic radiosurgery is indicated for solitary or oligometastatic disease.
Modern neurosurgical technologies maximise safe tumour removal: intraoperative MRI (iMRI) evaluates residual tumour before closing; 5-aminolevulinic acid (5-ALA) fluorescence causes malignant glioma cells to glow pink under violet light; neuronavigation guides the approach with millimetre accuracy; awake craniotomy with brain mapping preserves eloquent cortex during resection.
Gaf Healthcare connects patients with internationally accredited neurosurgical centres with intraoperative MRI, 5-ALA fluorescence, electrophysiological monitoring, and awake craniotomy capability.
Brain Tumour Types and WHO Grading
Brain tumours are classified by cell of origin and WHO grade (I–IV), reflecting aggressiveness and predicted behaviour:
Gliomas — from glial cells: Grade I (pilocytic astrocytoma — essentially benign); Grade II (diffuse low-grade — slow-growing but infiltrative); Grade III (anaplastic — requires chemotherapy and radiation); Grade IV Glioblastoma (GBM) — most common and aggressive primary brain tumour; median survival 14–16 months with standard treatment.
Meningiomas — from the meninges: Grade I (benign, 80% of cases) — complete resection is curative; Grades II–III have higher recurrence, may require post-operative radiation.
Pituitary adenomas — benign tumours causing hormonal dysfunction and optic chiasm compression. Managed by endoscopic transsphenoidal surgery.
Brain metastases — from primary tumours outside the brain (most commonly lung, breast, melanoma). Solitary or limited metastases are resectable; multiple are treated with stereotactic radiosurgery or whole-brain radiation.
The WHO CNS Tumour Classification 2021 now incorporates molecular markers (IDH mutation, 1p/19q codeletion, MGMT methylation) that profoundly influence prognosis and treatment response.
Who Is a Candidate for Brain Tumour Surgery?
Surgery is recommended when resection offers diagnostic clarity, symptomatic relief, or survival benefit that outweighs operative risk.
Resection candidates: patients with surgically accessible tumours causing mass effect, neurological deficit, or seizures; patients where maximum safe resection provides meaningful functional or survival benefit; and patients with solitary or limited brain metastases where systemic disease is controlled.
Biopsy-only candidates: patients with tumours in eloquent areas where resection carries unacceptable neurological deficit risk, or patients with multiple lesions requiring tissue diagnosis for treatment selection.
Stereotactic radiosurgery (SRS) candidates: small tumours (≤3–4 cm) accessible to focused radiation without opening the skull — used for brain metastases, acoustic neuromas, meningiomas, pituitary adenomas.
Contraindicated for surgery: GBM involving the brainstem or bilateral thalami; disseminated leptomeningeal carcinomatosis; Karnofsky performance status below 60; active systemic infection.
Pre-operative assessment includes MRI with gadolinium, CT for bony anatomy, functional MRI (fMRI) and DTI tractography for language and motor pathway mapping, and neuropsychological baseline documentation.
Craniotomy and Tumour Resection
Standard craniotomy is performed under general anaesthesia with the head fixed in a stereotactic clamp. A scalp incision is planned; a bone flap is elevated from the skull. The dura is opened, exposing the brain. Surgical navigation guides the approach trajectory. The operating microscope provides magnified visualisation. Ultrasonic aspiration (CUSA) fragments tumour while preserving blood vessels. 5-ALA fluorescence identifies tumour cells that are invisible under white light.
Electrophysiological monitoring — including cortical and subcortical stimulation during awake craniotomy, motor evoked potentials, and sensory evoked potentials — provides continuous feedback about neural integrity during resection.
Awake craniotomy uses an asleep-awake-asleep protocol where the patient is awakened during tumour resection. Direct stimulation mapping of language, motor, and speech areas in real-time — while the patient performs tasks — allows resection to the immediate functional cortex boundaries while preserving neurological function. Used for tumours adjacent to eloquent areas.
After tumour removal, the dura is closed, the bone flap replaced and secured with titanium plates, and the scalp closed. Total operating time: 3–8 hours depending on tumour size, location, and complexity.
Procedure Steps
- Pre-operative neuroimaging: MRI with gadolinium, fMRI, DTI tractography, CT for bony planning; neuronavigation dataset created.
- 5-ALA administration (for malignant glioma): capsules taken orally 3 hours before anaesthesia.
- Anaesthesia: general (or awake protocol for eloquent area tumours); head fixed in stereotactic clamp.
- Craniotomy: scalp incision; bone flap elevation; dural opening.
- Tumour resection: microscopic technique; CUSA ultrasonic aspiration; 5-ALA guidance; electrophysiological monitoring.
- Intraoperative MRI (if available): scan performed to assess residual tumour before closure.
- Wound closure: dural closure; bone flap replacement; patient to neurosurgical ICU.
- Post-operative MRI within 48 hours: gold standard for resection extent quantification.
Types of Brain Tumour Surgery
Standard Craniotomy with Microscopic Resection
Core neurosurgical procedure for most brain tumours. Bone flap elevation, dural opening, and microsurgical tumour removal under the operating microscope. Neuronavigation, intraoperative ultrasound, and 5-ALA fluorescence are standard adjuncts. Operating time 3–8 hours depending on tumour complexity.
Cost: $12,000 – $30,000
Awake Craniotomy with Brain Mapping
Performed under asleep-awake-asleep anaesthetic protocol. Direct cortical and subcortical electrical stimulation maps language and motor areas while patient performs tasks — enabling resection to functional boundaries without neurological damage. Used for tumours adjacent to eloquent motor and language cortex.
Cost: $16,000 – $38,000
Endoscopic Transsphenoidal Surgery (Pituitary Tumours)
Minimally invasive approach through the nostrils to the pituitary gland via the sphenoid sinus. No external incision; no brain retraction. Standard approach for pituitary adenomas. Endoscopic visualisation provides panoramic view. Typically 1–2 hours; 2–3 day hospital stay.
Cost: $8,000 – $20,000
Stereotactic Radiosurgery (SRS — Gamma Knife / CyberKnife)
Highly focused ablative radiation in 1–5 sessions. No incision; no anaesthesia. Effective for small tumours (≤3–4 cm): brain metastases, acoustic neuromas, meningiomas, selected gliomas. Local control rates comparable to surgery for small lesions. Used alone or as adjunct after surgical resection.
Cost: $8,000 – $20,000 (full course)
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
United States — $80,000 – $200,000 — Baseline
United Kingdom — $30,000 – $70,000 — ~65% vs. USA
Germany — $25,000 – $60,000 — ~68% vs. USA
India — $7,000 – $20,000 — Up to 90% vs. USA
UAE — $30,000 – $70,000 — ~65% vs. USA
Brain tumour surgery costs include the neurosurgical procedure, neurosurgical ICU stay (24–48 hours), and ward stay. Post-operative radiation (for malignant tumours) and chemotherapy (temozolomide for GBM — the Stupp protocol) are planned separately and represent ongoing treatment costs beyond the surgical episode.
Recovery & Follow-up
Recovery varies significantly by tumour type, location, and resection extent. Most patients spend 24–48 hours in neurosurgical ICU, then 3–7 days on the ward. Dexamethasone reduces peri-tumoral oedema and is tapered over 1–2 weeks. New neurological deficits from surgery may occur; oedema-related deficits often improve over 4–8 weeks. Physiotherapy, speech therapy, and occupational therapy begin as soon as the patient is able. For malignant tumours, radiation typically begins 4–6 weeks post-operatively.
Recovery Tips
- Take dexamethasone and anti-epileptic medications exactly as prescribed — never stop suddenly.
- Rest the first 2–3 weeks; gradually increase activity; avoid strenuous exercise for 6–8 weeks.
- Attend all post-operative appointments including 48-hour MRI and 3-month follow-up imaging.
- Report any new headache, vision change, weakness, confusion, or seizure immediately.
- Begin cognitive rehabilitation (OT, speech therapy) early if any deficit is present.
- Comply with driving restrictions in your jurisdiction.
- Attend oncology follow-up promptly — radiation starts typically 4–6 weeks post-operatively.
- Seek psychological support — a brain tumour diagnosis is profoundly distressing and mental health support improves recovery quality.
Risks & Complications
Operative mortality at high-volume neurosurgical centres is below 1–3% for most supratentorial tumours. Neurological morbidity — new motor, sensory, speech, or cognitive deficits — occurs in approximately 10–30% of patients and may be temporary (resolving as oedema settles) or permanent. Wound infection, intracranial haematoma, CSF leak, and hydrocephalus are additional complications. For malignant glioma, surgery is not curative; realistic patient and family counselling about GBM natural history is essential.
Why GAF Healthcare
Brain tumour surgery must be performed by high-volume neurosurgeons at centres with comprehensive infrastructure — neuronavigation, intraoperative MRI, 5-ALA capability, electrophysiological monitoring — and a complete multidisciplinary neuro-oncology team. Gaf Healthcare evaluates neurosurgical programme infrastructure, verifies surgeon tumour surgery volumes, and arranges pre-operative MRI and tumour board review before travel.
Frequently Asked Questions
What is 5-ALA fluorescence-guided surgery?
5-aminolevulinic acid (5-ALA, trade name Gliolan) causes malignant glioma cells to fluoresce pink under violet light filtered through the operating microscope. When taken orally 3 hours before surgery, it allows surgeons to see tumour cells invisible under white light, enabling more complete resection. The MODALAB trial demonstrated that 5-ALA fluorescence significantly increases complete resection rates and extends progression-free survival in glioblastoma.
What is awake brain surgery?
Awake craniotomy uses an asleep-awake-asleep anaesthetic protocol where the patient is awakened during tumour resection. The patient performs tasks — naming objects, moving limbs — while the surgeon uses electrical stimulation to map functional boundaries adjacent to the tumour. This allows safe resection up to the functional border, maximising tumour removal while avoiding neurological deficit.
What is the prognosis for glioblastoma?
With maximal safe resection followed by the Stupp protocol (concurrent temozolomide + radiotherapy, then adjuvant temozolomide), median survival is approximately 14–16 months; 5-year survival is approximately 5%. MGMT promoter methylation is the strongest positive prognostic factor, with methylated GBM achieving median survival of approximately 23 months.